Form 4: Immunome Inc. Executive Acquires 200,000 Stock Options
SEC Form 4 Filing
Robert Lechleider, Chief Medical Officer of Immunome Inc., reports the acquisition of 200,000 stock options.
Summary
- Robert Lechleider, the Chief Medical Officer of Immunome Inc., filed a Form 4 on August 13, 2024, reporting a transaction.
- The transaction involved the acquisition of 200,000 stock options with an exercise price of $12.92 on August 9, 2024.
- These options vest over time, with 25% vesting on August 9, 2025, and the remaining shares vesting monthly over the subsequent three years.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a standard executive compensation practice. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Comparing the size and vesting schedule of this grant to similar companies like Adaptive Biotechnologies or Legend Biotech would provide a benchmark for its competitiveness.
Key Dates
| Date | Description |
|---|---|
| 08/09/2024 | Date of the stock option grant. |
| 08/09/2025 | Date when 25% of the stock options vest. |
| 08/08/2034 | Expiration date of the stock options. |
| 08/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.